1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Growing Data-science Research in Africa to Stimulate Progress (GRASP) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. The GRASP program supports data-science research in Africa to stimulate progress. While the provided information is an award notice, it indicates an active program with a performance end date in July 2026, suggesting ongoing or upcoming related opportunities.
The NIH supports a diverse mix of research projects in Sub-Saharan Africa.
Get alerted about grants like this
Get emailed when new opportunities from “National Heart, Lung, and Blood Institute (NHLBI) / NIH” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Further details on specific eligibility for new applications would need to be confirmed on the official NIH or Grants.gov website, but generally NIH funds research from U.S. universities collaborating internationally. Confirm the full requirements in the official notice before applying.
The published deadline was July 31, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Growing Data-science Research in Africa to Stimulate Progress (GRASP) is funded by National Heart, Lung, and Blood Institute (NHLBI) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This program provides additional support for SBIR or STTR Phase II projects that require significant financing beyond the initial award to complete validation studies and obtain regulatory approval for products targeting heart, lung, blood, and sleep disorders.
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH HEAL Initiative. Supports action-oriented research under the NIH HEAL Initiative to accelerate the translation of evidence-based addiction prevention, treatment, and recovery interventions into routine practice, specifically focusing on non-addictive analgesic therapeutics.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
As of October 1, 2025, NIH no longer posts Notices of Funding Opportunity in the NIH Guide — Grants.gov is now the single official source (NOT-OD-25-143). The weekly Guide table-of-contents email that thousands of investigators relied on to discover funding no longer lists opportunities. Combined with the January 25, 2026 SciENcv certified-PDF requirement, the mechanics of finding and applying for NIH money have changed underneath everyone. Here is how to rebuild your discovery workflow so nothing slips through.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleThe NIH Director's New Innovator Award (DP2, RFA-RM-27-002) closes August 17, 2026, offering roughly 30 Early Stage Investigators up to $475,000 in direct costs a year for five years — $2.375 million total — to pursue bold ideas without the preliminary data a standard R01 demands. Here is how the High-Risk, High-Reward program actually evaluates applications, who qualifies, and why the usual R01 instincts will sink you.
Read article